+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

      The European Respiratory Journal

      Ambulatory Care, Antitubercular Agents, pharmacology, Communicable Disease Control, Extensively Drug-Resistant Tuberculosis, prevention & control, therapy, Guidelines as Topic, Humans, Mycobacterium tuberculosis, metabolism, Public Health, Sputum, Treatment Outcome, Tuberculosis, Multidrug-Resistant, World Health Organization

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the mandate of the World Health Organization (WHO) to support countries in the reinforcement of patient care. WHO commissioned external reviews to summarise evidence on priority questions regarding case-finding, treatment regimens for multidrug-resistant TB (MDR-TB), monitoring the response to MDR-TB treatment, and models of care. A multidisciplinary expert panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to develop recommendations. The recommendations support the wider use of rapid drug susceptibility testing for isoniazid and rifampicin or rifampicin alone using molecular techniques. Monitoring by sputum culture is important for early detection of failure during treatment. Regimens lasting ≥ 20 months and containing pyrazinamide, a fluoroquinolone, a second-line injectable drug, ethionamide (or prothionamide), and either cycloserine or p-aminosalicylic acid are recommended. The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens. Systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation. Scientific and medical associations should promote the recommendations among practitioners and public health decision makers involved in MDR-TB care. Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens.

          Related collections

          Author and article information




          Comment on this article